Hepanostika® HBsAg Ultra - New "ultra"-sensitive test for Hepatitis B infection from bioMérieux

07-Jul-2005

bioMérieux announced the launch of its new microelisa assay for the detection of hepatitis B surface antigen. The Hepanostika HBsAg Ultra assay offers state-of-the-art sensitivity and excellent specificity for the detection of hepatitis B surface antigen (HBsAg) in human plasma or serum. HBsAg is the most important marker for the diagnosis of acute or chronic hepatitis B virus (HBV) infection. In blood banks, routine screening of donor blood for HBsAg is mandatory to avoid transmission of hepatitis B. This has dramatically reduced the risk of post transfusion hepatitis B infection.

Hepanostika HBsAg Ultra enables detection of all known subtypes and clinically relevant variants of HBsAg using a convenient test procedure. The ability of the test to detect mutant antigen enables accurate patient diagnosis and ensures reliable screening of blood-transfusion products. Hepanostika HBsAg Ultra is a CE-marked in vitro diagnostic product and will initially be commercialized in Europe and the Middle-East.

Other news from the department research and development

Most read news

More news from our other portals

Is artificial intelligence revolutionizing the life sciences?